Effect of Trimetazidine on Myocardial Contractile Protein Troponin-T Destruction During Coronary Bypass Grafting

The aim of the present study was to evaluate the effect of trimetazidine (TMZ) on destruction of human ınyocardial contractile protein troponin-T during ischemia and reperfusion. The study was carried out on 30 patients undergoing aorto-coronary bypass surgery randomized to the TMZ group (composed of 15 patients) and the placebo group ( 15 patients) in NYHA Class III-IV Pretreatment was started three weeks before surgery with trimetazidine (60 mg orally per day) or placebo. In the TMZ group , there were 2 women and 13 men with a mean age of 57.1±2.2 and mean cross daınping time of 44±1.8 minutes. The placebo group, comprised 5 women and 10 men with a mean age of 58,4±1.2 and a mean cross clamping time of 42±2.4 minutes. Serial blood samples were collected before and after surgery for measure of serum concentrations of cardiac troponin-T. The preoperative serum concentration of TnT was measured 0-0.04 ng/ml in all patients whereas mean Troponin T levels were measured at 5 minutes after reperfusion (1.5±0.3ng/ml), 12h after surgery (ı .4±0. ıng/ml) and 24h after surgery (0.9±0. ıng/m l) and 48h. after surgery (0. ı ±0. ıng/ml) in the TMZ group. TnT levels of the placebo group measured at the same time periods were 4.4±0.4ng/ml, 4.8±0.7ng/ml, 2.8±0.4ng/ml and 0.7±0.lng/ml, respectively. In the TMZ group, TnT levels were significantly lower than those in the placebo group (pKeywords: Trimetazidine, cardiac troponin T, reperfusion injury, myocardial protection